On September 19, 2017 Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN, a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, reported that it will present at the Phacilitate Immuno-Oncology Frontiers Conference (Press release, Oncolytics Biotech, SEP 19, 2017, View Source [SID1234520576]). Dr. Andres Gutierrez, Oncolytics’ Chief Medical Officer, will present at 4:00 pm CEST on September 21, 2017 at the Maritim Proarte Hotel. The conference takes place on September 20th and 21st in Berlin, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on Oncolytics Biotech’s Cancer Pipeline, book your free 1stOncology demo here.

Dr. Gutierrez will highlight the role of REOLYSIN in the activation of the immune system and the induction of an inflamed tumor phenotype in the tumor microenvironment. His presentation will also review certain historical clinical programs, highlight the positive survival data from the IND 213 study in metastatic breast cancer (mBC) and the pooled safety database – the largest of any oncolytic virus.

"We want to share our extensive experience with REOLYSIN in the clinic to illustrate the specific expertise and efforts required to develop an oncolytic virus for intravenous administration and systemic exposure in oncology," said Dr. Gutierrez. "This experience helped us define a clear regulatory pathway for registration in metastatic breast cancer. With an overall agreement with the FDA on the phase 3 study design, details of the pivotal registration study will be made available following evaluation and completion of discussions with clinical advisors and potentially partners, as well as European regulators."

The Phacilitate Immuno-Oncology Frontiers conference hosts over 300 industry decision-makers and key external stakeholders to come together discuss and define a strategic roadmap to success for immuno-oncology developers, ensuring European patients gain access to the game-changing biotherapeutics of tomorrow. Immuno-Oncology frontiers Berlin is the only European event that offers extensive coverage of the latest emerging science whilst placing it in its wider strategic context as the basis of tomorrow’s successful business and commercialisation models.

About REOLYSIN
REOLYSIN is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers.

On September 19, 2017 Realist Pharma ("Realist" or "the Company") reported that it has entered into a collaboration and contribution agreement with the Canadian Glycomics Network ("GlycoNet") to assist in development of Realist’s glycomimetic vaccines targeting multiple cancers (Press release, realist pharma, SEP 19, 2017, View Source [SID1234532040]). In the context of this agreement, GlycoNet will provide a $250,000 financial contribution as well as key expertise for the scale-up of manufacturing of key precursors, for the subsequent GMP manufacturing of material for upcoming clinical studies. The funds will support the laboratory of Dr. H. Uri Saragovi at the Lady Davis Institute in Montréal, who will lead the development of these products. GlycoNet will receive an equity consideration for this contribution.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are indeed pleased to be collaborating with GlycoNet, an international leader in glycomics, on the development of our drug. Realist’s glycomimetic vaccines target the carbohydrate portions of well-known and widespread tumor markers, making an understanding of glycomics of signal importance to our future success," said Mark de Groot, Realist’s Chief Executive Officer. "While the initial focus of the collaboration is on the tumor marker gangliosides (TMGs) GD2 and GD3, Realist’s platform is expected to be able to address up to 20 different TMG targets in total."

"The research program developed by Realist and Dr. Saragovi at the Lady Davis Institute fits beautifully with GlycoNet’s mandate to advance glycomics for the benefit of Canadians by demonstrating the crucial role of glycomics in immuno-oncology. Realist’s novel discoveries demonstrate the relevance of glycomics for applications in human health and its potential for spurring job creation and start-up success in Canada," said Dr. Todd Lowary, GlycoNet Scientific Director. "We are extremely pleased to play a role in accelerating the commercial development of research that could lead to new cancer treatments as well as value creation in Canada."

On September 19, 2017 Petra Pharma, a drug development company focused on novel enzyme targets, and Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, reported a multi-target research collaboration to develop novel therapeutics for the treatment of cancer and metabolic diseases (Press release, Schrodinger, SEP 19, 2017, View Source [SID1234525274]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, the companies will work together to leverage Petra’s pipeline of unique enzyme targets and Schrödinger’s computational drug discovery platform in the design of novel small molecules for the treatment of cancer and metabolic diseases. Schrödinger will receive preclinical, clinical and commercial-stage milestone payments, as well as equity in Petra. Additional details and financial terms of the collaboration were not disclosed.

"Collaborating with Schrödinger gives us access to cutting-edge computational tools for drug design," said Brian O’Callaghan, President and Chief Executive Officer at Petra Pharma. "Combined with our expertise in novel enzyme targets, we look forward to leveraging this partnership to design and develop new treatment options for people with limited treatment options who suffer from cancer and metabolic diseases."

"We are looking forward to working with Petra’s highly talented team to accelerate the discovery of novel therapies." said Ramy Farid, Schrödinger’s President and CEO. "This partnership highlights the versatility of our computational drug discovery platform, which will support and enable Petra’s efforts to design innovative new drugs that may have an important impact on the lives of patients."

Petra Pharma is backed by a group of investors including AbbVie, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, 180 Degree Capital Corp., Empire State Development’s Innovate NY Fund, Johnson & Johnson Innovation – JJDC, Inc., Partnership Fund for New York City, Pfizer Venture Investments, Watson Fund and WuXi PharmaTech.

On September 19, 2017 Taiho Pharmaceutical Co., Ltd. announced today that it has entered into an option and license agreement with Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies (Press release, Taiho, SEP 19, 2017, View Source [SID1234527696]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on the terms of the agreement, Taiho will provide a $35mm payment to Arcus. In return for the payment, Taiho will receive an option to in-license the development and commercialization rights of product candidates in Arcus’s portfolio in Japan and certain other territories in Asia (excluding China). For any product candidate for which Taiho exercises a license, Taiho will need to provide option payments in development, regulatory and commercial milestones per molecule. Taiho is also need to pay royalties on the net sales of each product candidate that Taiho commercializes in its regions.

Taiho will attempt to continue delivering innovative new drugs to patients and medical professionals

On September 18, 2018 TOLREMO therapeutics AG ("TOLREMO"), a privately held research-stage biotechnology company, reported the completion of a fundraiser with private investors of 2.4 million Swiss Francs (Press release, TOLREMO, SEP 18, 2017, View Source [SID1234525826]). The proceeds will be used to advance the company’s discovery and development of breakthrough medicines to target drug resistance in cancer therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Stefanie Flückiger-Mangual, Chief Executive Officer and co-founder of TOLREMO, commented: "Cancer patients often respond favorably to modern therapies, but in many cases long-term survival is limited by the development of drug resistance. During several years of research at ETH Zurich, we discovered that, surprisingly, the development of drug resistance already starts early on following initiation of cancer therapy. We have developed a deep understanding of the molecular mechanisms involved in this and our goal is to intervene with these mechanisms in order to eradicate the seed of drug resistance and extend patient survival."

TOLREMO’s science-based drug discovery and development pipeline is fueled by a unique drug screening platform for which a patent has been filed. In addition to discovering and developing novel anti-drug resistance molecules, the platform is also used to identify novel ways of combining approved drugs to prevent drug resistance in cancer therapy.

Dr. Isaac Kobrin, Chairman of the Board and a co-founder of TOLREMO, commented: "We believe that TOLREMO is poised to reach several key milestones in the development of novel cancer therapies within the next 12 to 18 months. The currently raised funds of 2.4 million Swiss Francs are expected to cover that period and prepare the grounds for the future growth of the company."